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BACKGROUND: Diabetes is a major risk factor for atrial fibrillation (AF). However, it remains unclear whether individual AF phe-
notype and related comorbidities differ between patients who have AF with and without diabetes. This study investigated the 
association of diabetes with AF phenotype and cardiac and neurological comorbidities in patients with documented AF.
METHODS AND RESULTS: Participants in the multicenter Swiss- AF (Swiss Atrial Fibrillation) study with data on diabetes and AF 
phenotype were eligible. Primary outcomes were parameters of AF phenotype, including AF type, AF symptoms, and quality 
of life (assessed by the European Quality of Life- 5 Dimensions Questionnaire [EQ- 5D]). Secondary outcomes were cardiac 
(ie, history of hypertension, myocardial infarction, and heart failure) and neurological (ie, history of stroke and cognitive impair-
ment) comorbidities. The cross- sectional association of diabetes with these outcomes was assessed using logistic and linear 
regression, adjusted for age, sex, and cardiovascular risk factors. We included 2411 patients with AF (27.4% women; median 
age, 73.6 years). Diabetes was not associated with nonparoxysmal AF (odds ratio [OR], 1.01; 95% CI, 0.81– 1.27). Patients 
with diabetes less often perceived AF symptoms (OR, 0.74; 95% CI, 0.59– 0.92) but had worse quality of life (β=−4.54; 95% 
CI, −6.40 to −2.68) than those without diabetes. Patients with diabetes were more likely to have cardiac (hypertension [OR, 
3.04; 95% CI, 2.19– 4.22], myocardial infarction [OR, 1.55; 95% CI, 1.18– 2.03], heart failure [OR, 1.99; 95% CI, 1.57– 2.51]) and 
neurological (stroke [OR, 1.39, 95% CI, 1.03– 1.87], cognitive impairment [OR, 1.75, 95% CI, 1.39– 2.21]) comorbidities.
CONCLUSIONS: Patients who have AF with diabetes less often perceive AF symptoms but have worse quality of life and more 
cardiac and neurological comorbidities than those without diabetes. This raises the question of whether patients with diabetes 
should be systematically screened for silent AF.
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Diabetes is a major risk factor for atrial fibrillation (AF).1 The underlying mechanisms linking diabe-tes to AF involve electrical, structural, and auto-
nomic remodeling in the atria.2 In addition, metabolic 
alterations such as insulin resistance, inflammation, 
and abnormal hemostasis can lead to endothelial dys-
function and atherogenesis, which further predispose 
to AF development.3
Hypothetically, diabetes may also affect the individ-
ual manifestation of AF episodes. However, data are 
limited and previous studies have provided inconsis-
tent results.4– 6 One study reported that patients with 
diabetes have more sustained AF episodes and more 
pronounced AF symptoms.4 On the contrary, another 
study reported that patients with diabetes perceive AF 
symptoms less often than those without diabetes,5 
whereas few other studies found no association of dia-
betes with AF type or symptoms.6– 9 Moreover, the indi-
vidual perception of quality of life in patients who have 
AF with and without diabetes is currently unknown.
Diabetes can promote the development of hyper-
tension, myocardial infarction, and heart failure, thus 
creating a favorable substrate for the initiation and 
maintenance of AF.10– 12 Moreover, diabetes can pre-
dispose to neurological complications13,14 and has 
also been incorporated within risk scores for stroke 
prediction (eg, CHA2DS2- VASc or CHADS2 score) in 
patients with AF.15– 17 However, in light of the import-
ant advances in the management of diabetes over the 
past years, it remains unclear whether diabetes and 
antidiabetic medications are independently associated 
with cardiac and neurological comorbidities in patients 
with AF.
In this study, we hypothesized that AF phenotype 
and cardiac and neurological comorbidities differ be-
tween patients who have AF with and without diabetes. 
Our primary aim was to investigate the association of 
diabetes with parameters of AF phenotype, including 
AF type, AF symptoms, and quality of life. Our second-
ary aims were to investigate the association of diabetes 
with: (1) cardiac comorbidities, including history of hy-
pertension, myocardial infarction, heart failure; and (2) 




Patient informed consent forms, as approved by 
the responsible ethics committee (Ethikkommission 
Nordwest- und Zentralschweiz), do not allow the data 
to be made publicly available. The participants signed 
a consent form, which states that their data, contain-
ing personal and medical information, are exclusively 
available for research institutions in an anonymized 
form. Researchers interested in obtaining the data for 
research purposes can contact the Swiss- AF (Swiss 
Atrial Fibrillation) study scientific lead. Contact infor-
mation is provided on the Swiss- AF website (http://
www.swiss af.ch/conta ct.htm). Authorization of the re-
sponsible ethics committee is mandatory before the 
requested data can be transferred to external research 
institutions.
Study Population
The Swiss- AF study is an ongoing prospective cohort 
study including 2415 patients with a history of docu-
mented AF. The study protocol and objectives have 
been previously described in detail.18 Study partici-
pants were enrolled between 2014 and 2017 among 
14 centers in Switzerland. Patients were recruited by 
comprehensive screening in participating hospitals 
and/or by contacting general practitioners in the area. 
Patients were excluded if they had secondary forms 
of AF, had acute illness within the past 4  weeks, or 
were unable to provide informed consent. All data 
were collected in a standardized manner by trained 
CLINICAL PERSPECTIVE
What Is New?
• In this multicenter cohort study of 2411 patients 
with documented atrial fibrillation, we found that 
patients with diabetes less often perceive atrial 
fibrillation symptoms, although they have worse 
quality of life and more cardiac and neurological 
comorbidities than patients without diabetes.
What Are the Clinical Implications?
• Our findings further raise the question of 
whether patients with diabetes should be sys-
tematically screened for silent atrial fibrillation.
• Patients with concomitant AF and diabetes de-
serve more attentive care.
Nonstandard Abbreviations and Acronyms
EQ- 5D European Quality of Life- 5 
Dimensions Questionnaire
MoCA Montreal Cognitive Assessment
ORBIT- AF Outcomes Registry for Better 
Informed Treatment of Atrial 
Fibrillation
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study personnel. At enrollment, participants under-
went a clinical examination, blood sampling, cognitive 
assessment, quality- of- life assessment, and 5- minute 
resting 16- lead ECG. Detailed information on personal 
characteristics, risk factors, and comorbidities was ob-
tained through standardized case report forms, which 
have been previously validated.18,19 The Swiss AF study 
was approved by local research ethics committees in 
all participating sites. Each study participant provided 
written informed consent. For the current analysis, 
participants of the Swiss- AF study with complete data 
available on diabetes and AF phenotype were consid-
ered eligible (Figures S1 and S2).
Assessment of Diabetes and Antidiabetic 
Medication
Diabetes was defined on the basis of documented 
medical history and use of antidiabetic treatment. 
Participants were classified according to the use of 
antidiabetic medications into: patients without diabe-
tes, patients with noninsulin- requiring diabetes, and 
patients with insulin- requiring diabetes. Participants 
were classified as having noninsulin- requiring diabetes 
if they had a diagnosis of diabetes and were on a diet 
and/or taking antidiabetic medications other than in-
sulin/insulin analogues. Participants were classified as 
having insulin- requiring diabetes if they had a diagnosis 
of diabetes and were taking insulin/insulin analogues.
Assessment of AF Phenotype
AF type was determined by the local study investiga-
tor during the baseline visit on the basis of all available 
clinical patient data over the years before enrollment, 
documented by medical records, ECG, and/or rhythm 
monitoring device. AF type was classified into parox-
ysmal, persistent, and permanent AF according to the 
guidelines of the European Society of Cardiology.20 
Paroxysmal AF was defined as self- terminating AF last-
ing <7 days and that did not require cardioversion and 
that was documented at least twice within the past 
5 years.20 Persistent AF was defined as AF sustained 
for at least 7 days and/or AF requiring cardioversion, 
documented within the past 5 years by ECG or rhythm 
monitoring devices.20 Permanent AF was defined as 
AF in which cardioversion therapy failed or was not 
attempted.20 To assess the association of diabetes 
with self- terminating versus nonself- terminating AF, the 
study participants were categorized as having parox-
ysmal and nonparoxysmal AF.
Participants provided detailed information on AF- 
related symptoms, including palpitations, dizziness, 
chest pain, exercise intolerance, dyspnea, tiredness, 
syncope, or other symptoms.
Quality of life was measured based on the European 
Quality of Life- 5 Dimensions Questionnaire (EQ- 5D), 
which is a widely used, nondisease- specific instru-
ment.18,21 EQ- 5D was composed of 5 domains, includ-
ing mobility, self- care, usual activities, pain/discomfort, 
and anxiety/depression. For each of the 5 domains, 
participants selected 1 of the following responses: 
“no problems,” “some problems,” or “extreme prob-
lems.” Moreover, the instrument includes a visual an-
alogue scale, on which participants score their health 
state between 0 (worst imaginable health state) and 
100 (best imaginable health state).22 Hence, the score 
ranges from 0 to 100, with higher values indicating bet-
ter quality of life.
Assessment of Cardiac and Neurological 
Comorbidities
Information on the history of hypertension, myocardial 
infarction, and heart failure was collected from pa-
tients’ reports and medical records. History of heart 
failure was clinically defined as a syndrome in which 
patients had typical symptoms (eg, breathlessness, 
ankle swelling, and fatigue) and typical signs (eg, el-
evated jugular venous pressure, pulmonary crackles, 
and displaced apex beat) related to abnormalities of 
cardiac structure or function.
Information on the history of stroke was collected 
from the patients’ reports and verified by medical re-
cords. Neurocognitive function was assessed by cal-
culating the Montreal Cognitive Assessment (MoCA) 
score. MoCA score evaluated various domains of 
cognitive and executive functions, including visuospa-
tial ability, memory, orientation, abstraction, language, 
mental flexibility, and attention.18,23 Each patient could 
obtain a minimum of 0 points and a maximum of 30 
points, with higher scores indicating a better neuro-
cognitive function. For those who achieved <30 points 
and had ≤12 years of education, 1 point was added 
to the MoCA total score.18 Cognitive impairment was 
defined as a MoCA score of ≤25.23
Additional Measurements
Smoking status was classified as current, former, 
and never smoking. Body weight was obtained from 
each participant in light clothing and without shoes 
using a calibrated device. Body height was measured 
without shoes using a calibrated device. Body mass 
index was calculated as weight in kilograms divided 
by height in meters squared. Extensive information 
on medication intake, such as use of anticoagulation 
medications (including vitamin K antagonists and non-
vitamin K antagonists), antiarrhythmic medications (in-
cluding amiodarone, dronedarone, sotalol, flecainide, 
and propafenone), and β- blockers, was obtained from 
the patients` reports and verified by medical records. 
Additional information on prior procedures, includ-
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cardioversion, was obtained. Rhythm control interven-
tion was defined as either a pulmonary vein isolation 
and/or electrical cardioversion and/or use of antiar-
rhythmic medications, which altogether represent the 
most effective rhythm control intervention currently 
available. We also calculated CHA2DS2- VASc score, 
which includes congestive heart failure; hypertension; 
age ≥75  years; diabetes; prior stroke, transient is-
chemic attack, or thromboembolism; vascular disease; 
age 65 to 74 years; and sex (female). In a subsample of 
our population, left ventricular ejection fraction (LVEF) 
and left atrial size (diameter in parasternal long axis) 
were measured by transthoracic echocardiography, 
which was performed within the last 3 months before 
the patients’ enrollment.
Statistical Analysis
Baseline characteristics were stratified by absence or 
presence of diabetes. Categorical variables were pre-
sented as numbers (percentages), and between- group 
differences were compared using Pearson chi- square 
tests. Continuous variables were presented as mean 
(±SD) or median (interquartile range), and between- 
group differences were compared using Wilcoxon rank 
sum tests.
We used logistic regression to cross- sectionally 
investigate the association of diabetes (no versus 
yes) and antidiabetic medication (no diabetes versus 
noninsulin- requiring diabetes versus insulin- requiring 
diabetes) with AF symptoms (no versus yes), AF type 
(paroxysmal versus nonparoxysmal), history of hyper-
tension (no versus yes), history of myocardial infarction 
(no versus yes), history of heart failure (no versus yes), 
history of stroke (no versus yes), and cognitive impair-
ment (no versus yes). Odds ratios (ORs) and 95% CIs 
were reported. We used ordinary least- squares linear 
regression to investigate the association of diabetes 
and antidiabetic medication with quality- of- life score. β 
Coefficients and CIs were reported.
For the analyses, 2 models were created. The first 
model (model 1) was adjusted for age (continuous) and 
sex (men versus women). The second model (model 
2) was adjusted for potential confounders that were 
selected based on biological plausibility and previous 
literature. For the analyses on AF symptoms, model 
2 was adjusted for age (continuous), sex (men versus 
women), use of β- blockers (no versus yes), and use 
of antiarrhythmic medications (no versus yes). For the 
other analyses, model 2 was adjusted for age (contin-
uous), sex (men versus women), smoking status (never 
versus former versus current), body mass index (con-
tinuous), and (in case hypertension was not the out-
come) history of hypertension (no versus yes).
Assumptions for logistic regression were checked 
and met. Multicollinearity was examined to ensure that 
continuous independent variables were not closely 
correlated. Assumptions for linear regression were 
checked, and no violations were observed. The as-
sumption of homoscedasticity was checked by ex-
amining plots of the residuals versus the fitted values. 
The possibility of multicollinearity was assessed by 
the variance inflation factor. The influential points were 
inspected with Cook`s distance. The assumption of 
independence of residuals was checked by Durbin 
Watson test. The assumption of normal distribution of 
error terms was checked by examining plots of the re-
siduals. We checked for potential effect modification 
by separately adding product interaction terms of the 
exposure with each of the covariates of the most ad-
justed model, but none of the interaction terms were 
significant. Multiple imputations were performed in 
case of missing covariates. Statistical analyses were 
performed using SPSS version 21 (IBM) and R statis-
tical software (rms package, R Project for Statistical 
Computing, Institute for Statistics and Mathematics, R 
Core Team, version 4.0.1).
Sensitivity Analyses
To test the robustness of our findings, we performed 
the following sensitivity analyses:
1. To evaluate the potential influence of study cen-
ters on our results, we additionally adjusted our 
analyses for study centers.
2. To account for a potential influence of AF duration 
on our results, we additionally adjusted our analyses 
for AF duration (ie, time since first documented AF 
episode); and we stratified our analyses by median 
AF duration (ie, 3.6 years).
3. To account for a potential influence of rhythm control 
strategy on our results, we additionally adjusted our 
analyses for rhythm control intervention.
4. To account for a potential influence of anticoagulation 
medications on our results, we additionally adjusted 
our analyses for use of anticoagulation medications.
5. We separately explored the association of diabe-
tes with the 5 domains of the quality- of- life score, 
namely mobility (no impairment versus moderate 
or extreme impairment), self- care (no impairment 
versus moderate or extreme impairment), usual ac-
tivities (no impairment versus moderate or extreme 
impairment), pain/discomfort (no pain/discomfort 
versus moderate or extreme pain/discomfort), and 
anxiety/depression (no anxiety/depression versus 
moderate or extreme anxiety/depression).
6. To evaluate the impact of diabetes on cardiac struc-
ture and function, we investigated the association 
of diabetes and antidiabetic medication with left 
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7. We evaluated potential sex differences by perform-
ing the analyses in men and women separately.
RESULTS
Of a total of 2415 patients enrolled in the Swiss- AF 
cohort study, complete data on history of diabetes 
and AF phenotype parameters were available in 2411 
(99.8%) patients (Figure S1). Of these, 420 (17.4%) had 
known diabetes (Table  1). The baseline characteris-
tics of the study population are shown in Table 1. The 
mean age was 73.2 years; the median age was 73.6 
years (interquartile range, 68.2– 78.0 years); and 27.4% 
were women (Table 1). Compared with those without 
diabetes, patients with diabetes were more frequently 
older, men, smokers, and had a higher body mass 
index (Table  1). Patients with diabetes had a higher 
stroke risk compared with those without diabetes as 
estimated by median CHA2DS2- VASc score (5 versus 
3, P<0.001).
Diabetes and AF Phenotype
Diabetes and antidiabetic medications were not asso-
ciated with AF type (Tables 2 and 3, Figure, Figure S3). 
Compared with patients without diabetes, patients 
with diabetes less often perceived AF symptoms (OR, 
0.75; 95% CI, 0.61– 0.94 in patients with diabetes; 
OR, 0.64; 95% CI, 0.44– 0.92 in patients with insulin- 
requiring diabetes) (Tables 2 and 3, Figure, Table S1, 
Figure S3).
Patients with diabetes had worse quality of life 
(predicted mean difference in EQ- 5D score: β, −6.35; 
95% CI, −8.15 to −4.54 in patients with diabetes; β, 
−8.59; 95% CI, −11.6 to −5.54 in patients with insulin- 
requiring diabetes) compared with patients without di-
abetes (Tables 2 and 3, Figure, Figure S3). When we 
focused our analyses on the specific domains of the 
quality- of- life score, we observed that diabetes was 
associated with impaired mobility, self- care, and usual 
activities but was not associated with anxiety/depres-
sion (Table S2). Overall, the results did not substantially 
change after primary and additional adjustments for 
potential confounders; therefore, we further report the 
most adjusted model (model 2).
Diabetes and Cardiac Comorbidities
Patients with diabetes were more likely to have a his-
tory of hypertension (OR, 3.04; 95% CI, 2.19– 4.22), my-
ocardial infarction (OR, 1.55; 95% CI, 1.18– 2.03), and 
heart failure (OR, 1.99; 95% CI, 1.57– 2.51) compared 
with patients without diabetes (Table 4, Figure). In par-
ticular, patients with insulin- requiring diabetes were 
more likely to have a history of myocardial infarction 
(OR, 2.40; 95% CI, 1.60– 3.62) and heart failure (OR, 
2.44; 95% CI, 1.67– 3.55) (Table 3, Figure S3).
For a subset of patients, echocardiographic data 
on LVEF (n=711) and left atrial size (n=476) were avail-
able. We observed similar baseline characteristics: (1) 
when comparing participants with and without data 
available on left atrial size; and (2) when comparing 
participants with and without data available on LVEF 
(Table S3). Patients with diabetes had a higher mean 
left atrial size and lower mean LVEF than patients 
without diabetes (Table 1). However, the association 
of diabetes with echocardiographic parameters did 
not reach statistical significance in the most adjusted 
model (Table S4).
Diabetes and Neurological Comorbidities
Compared with patients without diabetes, patients with 
diabetes were more likely to have a history of stroke 
(OR, 1.39; 95% CI, 1.03– 1.87) and cognitive impair-
ment (OR, 1.75; 95% CI, 1.39– 2.21) (Table 4, Figure). In 
particular, patients with insulin- requiring diabetes were 
more likely to have cognitive impairment (OR, 2.30; 
95% CI, 1.55– 3.41) (Table 3, Figure S3).
Additional Analyses
Results were similar in men and women. The sensitivity 
analyses adjusting for study centers and AF duration 
and stratifying by median AF duration provided con-
sistent results. The sensitivity analyses adjusting for 
rhythm control intervention and use of anticoagulation 
medications provided consistent results (Table S5).
DISCUSSION
In a large cohort of 2411 patients with documented AF, 
we investigated whether patients with and without dia-
betes differ in terms of AF phenotype and comorbidi-
ties. We showed that patients with diabetes less often 
perceive AF symptoms, but have worse quality of life 
and more cardiac and neurological comorbidities than 
patients without diabetes.
Previous evidence on the association of diabetes 
with AF symptoms has been scarce and controver-
sial.4,8 One study did not find an association between 
diabetes and AF symptoms in a cohort of patients with 
new- onset AF.8 Nevertheless, this study may have 
been underpowered, as it included a smaller sam-
ple size compared with ours. Another study, which 
was performed in an American AF cohort (ORBIT- AF 
[Outcomes Registry for Better Informed Treatment of 
Atrial Fibrillation]), evaluated the prevalence of specific 
AF symptoms in patients with and without diabetes.4 
The study reported that patients with diabetes expe-
rience fewer episodes of palpitations or syncope and 
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Table 1. Baseline Characteristics of Included Participants*
All (n=2411) No diabetes (n=1991) Diabetes (n=420) P value†
Age, y 73.2 (8.4) 73.0 (8.5) 74.2 (7.7) 0.02
Women, n (%) 661 (27.4) 583 (29.3) 78 (18.6) <0.001
Smoking, n (%) <0.001
Current 175 (7.3) 127 (6.4) 48 (11.4)
Former 1180 (48.9) 933 (46.9) 247 (58.8)
Never 1056 (43.8) 931 (46.8) 125 (29.8)
Body mass index, kg/m2 27.7 (4.7) 27.2 (4.5) 29.8 (5.2) <0.001
Systolic blood pressure, mm Hg 133.8 (18.7) 133.7 (18.8) 134.6 (18.2) 0.3
Diastolic blood pressure, mm Hg 77.3 (11.8) 77.7 (11.7) 75.7 (12.3) 0.001
Diabetes treatment, n (%)
Diet alone, no antidiabetic treatment 80 (19)
Intake of antidiabetic medication 
other than insulin or insulin 
analogue
212 (50.5)
Intake of insulin or insulin analogue 128 (30.5)
AF duration, y 3.6 (0.9– 8.5) 3.5 (0.9– 8.1) 3.8 (0.9– 9.9) 0.08
CHA2DS2- VASc score 3 (2– 5) 3 (2– 4) 5 (4– 6) <0.001
CHA2DS2- VASc score, n (%)
0 83 (3.4) 83 (4.2) 0 (0)
1 218 (9) 218 (10.9) 0 (0)
2 411 (17) 397 (19.9) 14 (3.3)
3 527 (21.9) 469 (23.6) 58 (13.8)
4 502 (20.8) 407 (20.4) 95 (22.6)
5 369 (15.3) 256 (12.9) 113 (26.9)
6 201 (8.3) 112 (5.6) 89 (21.2)
7 78 (3.2) 42 (2.1) 36 (8.6)
8 19 (0.8) 4 (0.2) 15 (3.6)
Use of oral anticoagulation, n (%) 2179 (90.3) 1789 (89.9) 389 (92.6) 0.08
Use of vitamin K antagonist 950 (39.4) 746 (37.5) 204 (48.6) <0.001
Use of nonvitamin K antagonist 1227 (50.9) 1043 (52.4) 184 (43.8) 0.001
Use of antiarrhythmic medications, 
n (%)
516 (21.4) 439 (22) 77 (18.3) 0.09
Use of β- blockers, n (%) 1695 (70.3) 1357 (68.2) 338 (80.5) <0.001
Prior procedures, n (%)
History of pulmonary vein isolation 489 (20.3) 443 (22.3) 46 (11) <0.001
History of electrical cardioversion 861 (35.7) 712 (35.8) 149 (35.5) 0.9
Rhythm control intervention, n (%) 1311 (54.4) 1111 (55.8) 200 (47.6) 0.002
Any AF symptoms, n (%) 1493 (61.9) 1266 (63.6) 227 (54) <0.001
Palpitations 871 (36.1) 761 (38.2) 110 (26.2) <0.001
Dizziness 341 (14.1) 280 (14.1) 61 (14.5) 0.8
Chest pain 237 (9.8) 190 (9.5) 47 (11.2) 0.3
Exercise intolerance 539 (22.4) 464 (23.3) 75 (17.9) 0.01
Dyspnea 589 (24.4) 486 (24.4) 103 (24.5) 0.9
Tiredness 386 (16) 323 (16.2) 63 (15) 0.5
Syncope 78 (3.2) 65 (3.3) 13 (3.1) 0.8
Other symptoms 336 (13.9) 294 (14.8) 42 (10) 0.01
AF type, n (%) 0.07





 http://ahajournals.org by on N
ovem
ber 11, 2021
J Am Heart Assoc. 2021;10:e021800. DOI: 10.1161/JAHA.121.021800 7
Bano et al Diabetes and Atrial Fibrillation Phenotype
tiredness compared with patients without diabetes. 
These results, however, need to be interpreted with 
caution, given that the study did not account for poten-
tial confounding factors such as age, sex, β- blockers, 
antiarrhythmic medications, or ethnicity.4 Conversely, 
our study comprehensively assessed the overall 
burden of any AF symptoms in patients with and with-
out diabetes, also accounting for confounders.
Various factors can explain the reduced manifesta-
tion of AF symptoms in patients with diabetes. First, a 
potential mechanism through which diabetes can affect 
AF symptoms is cardiac autonomic neuropathy. This 
All (n=2411) No diabetes (n=1991) Diabetes (n=420) P value†
Nonparoxysmal AF 1333 (55.3) 1084 (54.5) 249 (59.3)
Nonparoxysmal AF
Persistent AF 737 (30.6) 619 (31.1) 118 (28.1)
Permanent AF 596 (24.7) 465 (23.4) 131 (31.2)
Quality of life 72.1 (17.4) 73.3 (17.0) 66.9 (18.5) <0.001
History of hypertension, n (%) 1684 (69.8) 1311 (65.8) 373 (88.8) <0.001
History of myocardial infarction, n (%) 390 (16.2) 284 (14.3) 106 (25.2) <0.001
History of heart failure, n (%) 625 (25.9) 454 (22.8) 171 (40.7) <0.001
Left atrial size, mm 44.6 (7.8) 44.3 (7.9) 46.3 (7.2) 0.04
LVEF (%) 54.3 (11.8) 54.7 (11.4) 52.2 (11.9) 0.02
LVEF <50%, n (%) 188 (7.8) 150 (7.5) 38 (9) 0.08
History of stroke, n (%) 318 (13.2) 245 (12.3) 73 (17.4) 0.005
Neurocognitive function (MoCA score) 25.3 (3.1) 25.6 (3.1) 24.1 (3.4) <0.001
Rhythm control intervention was defined as either a history of pulmonary vein isolation and/or electrical cardioversion and/or use of antiarrhythmic 
medications, which altogether represent the most effective rhythm control interventions currently available. 
AF indicates atrial fibrillation; CHA2DS2- VASc score includes congestive heart failure; hypertension; age ≥75 years; diabetes; prior stroke, transient ischemic 
attack, or thromboembolism; vascular disease; age 65 to 74 years; and sex (female); LVEF indicates left ventricular ejection fraction.
*Data are presented as mean (SD) or median (interquartile range), unless otherwise specified. Data on history of heart failure and data on history of stroke 
were available in 2409 and 2410 participants, respectively. Data on neurocognitive function were available in 2398 participants. Echocardiographic data on 
indicates left atrial size and ejection fraction were available in a subsample of 476 and 711 participants, respectively.
†For categorical variables, differences between groups were compared using the Pearson chi- square test. For continuous variables, differences between 
groups were compared using the Wilcoxon rank sum test. The quality- of- life score ranges from 0 to 100, with higher values indicating better quality of life. The 
Montreal Cognitive Assessment (MoCA) score ranges from 0 to 30, with higher values indicating better neurocognitive function.
Table 1. Continued
Table 2. Association of Diabetes With AF Phenotype*
Model 1 Model 2
OR (95% CI) OR (95% CI)
Nonparoxysmal AF 1.13 (0.91 to 1.41) 1.01 (0.81 to 1.27)
Any AF symptoms 0.75 (0.61 to 0.94)† 0.74 (0.59 to 0.92)†
Palpitations 0.65 (0.51 to 0.83)† 0.64 (0.50 to 0.81)†
Dizziness 1.12 (0.83 to 1.52) 1.12 (0.83 to 1.52)
Chest pain 1.33 (0.95 to 1.88) 1.29 (0.91 to 1.83)
Exercise intolerance 0.76 (0.58 to 0.99)† 0.76 (0.58 to 1.01)
Dyspnea 1.07 (0.84 to 1.37) 1.04 (0.81 to 1.33)
Tiredness 1.01 (0.75 to 1.36) 1.02 (0.76 to 1.38)
Syncope 1.02 (0.55 to 1.88) 0.99 (0.54 to 1.83)
Other symptoms 0.70 (0.50 to 1.00) 0.70 (0.49 to 0.99)†
β (95% CI) β (95% CI)
Quality of life −6.35 (−8.15 to −4.54)† −4.54 (−6.40 to −2.68)†
Model 1: adjusted for age and sex. 
Model 2 for outcomes “AF type” and “quality of life”: adjusted for age, sex, smoking status, body mass index, and prevalent hypertension. Model 2 for 
outcome “AF symptoms”: adjusted for age, sex, use of β- blockers, and use of antiarrhythmic medications. 
AF indicates atrial fibrillation; and OR, odds ratio.
*The beta regression coefficients (β) indicate predicted differences in mean quality- of- life score between patients with diabetes and those without diabetes 
(reference). The quality- of- life score ranges from 0 to 100, with higher values indicating better quality of life.
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complication of diabetes is typically known for mask-
ing cardiac symptoms secondary to myocardial infarc-
tion.24– 26 In a similar manner, diabetes- induced cardiac 
autonomic neuropathy can decrease the sensitivity of 
cardiac nerves and eventually attenuate the perception 
of AF symptoms.27 Second, patients who had AF with 
diabetes in our cohort had a slightly longer AF duration 
and a more frequent use of β- blockers than patients 
without diabetes. The reduced manifestation of AF 
symptoms might thus be attributable to the relatively 
Table 3. Association of Antidiabetic Medication With AF Phenotype and Cardiac and Neurological Comorbidities†
Model 1 Model 2
Antidiabetic medication and AF phenotype
Nonparoxysmal AF OR (95% CI) OR (95% CI)
No diabetes 1 (Reference) 1 (Reference)
Noninsulin- requiring diabetes 1.27 (0.99 to 1.64) 1.15 (0.88 to 1.50)
Insulin- requiring diabetes 0.88 (0.61 to 1.26) 0.76 (0.53 to 1.10)
Any AF symptoms* OR (95% CI) OR (95% CI)
No diabetes 1 (Reference) 1 (Reference)
Noninsulin- requiring diabetes 0.81 (0.63 to 1.05) 0.80 (0.62 to 1.04)
Insulin- requiring diabetes 0.64 (0.44 to 0.92)‡ 0.61 (0.42 to 0.89)‡
Quality of life* β (95% CI) β (95% CI)
No diabetes 0 (Reference) 0 (Reference)
Noninsulin- requiring diabetes −5.36 (−7.46 to −3.26)‡ −3.62 (−5.77 to −1.48)‡
Insulin- requiring diabetes −8.59 (−11.6 to −5.54)‡ −6.65 (−9.73 to −3.57)‡
Antidiabetic medication and cardiac comorbidities
Hypertension OR (95% CI) OR (95% CI)
No diabetes 1 (Reference) 1 (Reference)
Noninsulin- requiring diabetes 4.82 (3.22 to 7.21)‡ 3.79 (2.51 to 5.71)‡
Insulin- requiring diabetes 2.84 (1.73 to 4.69)‡ 1.96 (1.17 to 3.27)‡
Myocardial infarction* OR (95% CI) OR (95% CI)
No diabetes 1 (Reference) 1 (Reference)
Noninsulin- requiring diabetes 1.45 (1.06 to 1.98)‡ 1.24 (0.90 to 1.71)
Insulin- requiring diabetes 2.71 (1.82 to 4.04)‡ 2.40 (1.60 to 3.62)‡
Heart failure* OR (95% CI) OR (95% CI)
No diabetes 1 (Reference) 1 (Reference)
Noninsulin- requiring diabetes 2.03 (1.57 to 2.64)‡ 1.82 (1.39 to 2.38)‡
Insulin- requiring diabetes 2.66 (1.84 to 3.84) 2.44 (1.67 to 3.55)‡
Antidiabetic medication and AF- related complications
Stroke OR (95% CI) OR (95% CI)
No diabetes 1 (Reference) 1 (Reference)
Noninsulin- requiring diabetes 1.54 (1.11 to 2.15)‡ 1.45 (1.04 to 2.04)‡
Insulin- requiring diabetes 1.28 (0.78 to 2.11) 1.23 (0.74 to 2.05)
Cognitive impairment* OR (95% CI) OR (95% CI)
No diabetes 1 (Reference) 1 (Reference)
Noninsulin- requiring diabetes 1.74 (1.35 to 2.25)‡ 1.57 (1.21 to 2.04)‡
Insulin- requiring diabetes 2.57 (1.74 to 3.80)‡ 2.30 (1.55 to 3.41)‡
Model 1: adjusted for age and sex. 
Model 2 for outcome AF symptoms: adjusted for age, sex, use of β- blockers, and use of antiarrhythmic medications; model 2 for other outcomes: adjusted 
for age, sex, smoking status, body mass index, and (in case hypertension is not the outcome) prevalent hypertension. 
AF indicates atrial fibrillation; and OR, odds ratio.
*For this analysis, participants were classified into: patients without diabetes (reference), patients with noninsulin- requiring diabetes, and patients with 
insulin- requiring diabetes. Data on history of hypertension and history of myocardial infarction were available in 2411 participants. Data on history of heart 
failure and history of stroke were available in 2409 and 2410 participants, respectively. Data on cognitive impairment were available in 2398 participants. The 
beta regression coefficients (β) indicate predicted differences in mean values between patients without diabetes (reference), patients with noninsulin- requiring 
diabetes, and patients with insulin- requiring diabetes. The quality- of- life score ranges from 0 to 100, with higher values indicating better quality of life.
†Results suggest a dose- response association.
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long AF duration and use of β- blockers, rather than be-
cause of diabetes itself. However, our results did not 
change after adjusting for or stratifying by AF duration 
or β- blockers, indicating that the link between diabetes 
and AF symptoms is independent of these factors.
One can also hypothesize that the hyperglycemic 
state favors AF progression and occurrence of nonpar-
oxysmal AF episodes by altering cardiac morphology 
and electrophysiologic properties.4,28 However, the 
available evidence on the association of diabetes with 
AF progression is inconclusive. Some studies not ac-
counting for cardiovascular risk factors have reported 
that patients with diabetes have an increased like-
lihood of nonparoxysmal AF.29,30 On the other hand, 
studies accounting for cardiovascular risk factors have 
usually not detected an association between diabetes 
and AF progression.9,31 Our study did not find an as-
sociation of diabetes with AF progression. This result 
needs to be interpreted with caution and we cannot 
rule out that our study might have been underpowered 
to detect an association. In the raw model, as well as 
in the age- and sex- adjusted model, we observed a 
borderline significant association, with an OR of 1.13. 
The effect estimate was largely attenuated (ie, OR, 
1.01) after additionally adjusting for cardiovascular risk 
factors such as obesity and hypertension, which may 
also be involved in the pathways that link diabetes to 
AF progression.12,32 Future adequately powered stud-
ies with long- term follow- up are needed to explore the 
interplay between glycemic fluctuations, diabetes, and 
other cardiovascular risk factors in relation to AF pro-
gression over time. Additional mechanisms that can 
explain the link between diabetes and AF progression 
remain to be further elucidated.
Over the past decades, several studies have con-
sistently reported a worse quality of life in patients who 
have AF with diabetes compared with those without 
diabetes.4,8,29,33 Despite advances in the management 
of diabetes, our study confirmed that these differences 
in quality of life still exist. Most likely, the lower quality 
of life in patients who have AF with diabetes can be as-
cribed to their increased prevalence of comorbidities. 
This is supported by our data, showing that patients 
who have AF with diabetes have more cardiac (hyper-
tension, myocardial infarction, and heart failure) and 
neurological (stroke and cognitive impairment) comor-
bidities than patients without diabetes. Notably, our 
study provides novel insights by revealing significant 
differences in the neurocognitive function of patients 
who have AF with and without diabetes. Two previous 
studies, which were characterized by relatively small 
sample sizes of patients with AF (n=260 and n=218) 
and lack of adjustment for potential confounding, were 
not able to detect an association of diabetes with neu-
rocognitive function.14,34
We further evaluated the clinical characteristics 
of patients with insulin- requiring diabetes, those with 
noninsulin- requiring diabetes, and those without dia-
betes, respectively. Of these, patients with diabetes 
on insulin therapy generally manifested less AF symp-
toms and more comorbidities. A potential explanation 
for this result is that elevated concentrations of insulin 
in the setting of insulin resistance can promote ath-
erosclerosis and AF- related complications.35,36 On the 
other hand, it is also plausible that insulin intake may 
reflect long- standing diabetes, which is character-
ized by prolonged exposure to hyperglycemia. In turn, 
chronic exposure to hyperglycemia and/or poor gly-
cemic control promote the accumulation of glycation 
end products, which can favor the development of car-
diac autonomic neuropathy, reduced perception of AF 
symptoms, and increased likelihood of comorbidities. 
Based on these mechanisms, one can assume that 
among patients with diabetes, especially those with 
insulin- requiring diabetes, those with prolonged diabe-
tes duration and/or those with poor glycemic control 
can have a reduced perception of AF symptoms. This 
assumption needs to be addressed by further studies 
with data available on diabetes duration and glycemic 
control. Future observational and experimental studies 
are also needed to prospectively investigate the poten-
tial impact of insulin and novel antidiabetic treatments 
(especially glucagon- like peptide- 1 receptor agonists 
and sodium- glucose transport protein 2 inhibitors) on 
the overall health of patients with AF.
Strengths and Limitations
Our study has several strengths. Using a compre-
hensive approach, we provide information on AF 
Table 4. Association of Diabetes With Cardiac and 
Neurological Comorbidities†
Model 1 Model 2
OR (95% CI) OR (95% CI)
Association of diabetes with cardiac comorbidities
Hypertension 4.01 (2.91– 5.53) 3.04 (2.19– 4.22)
Myocardial 
infarction
1.79 (1.38– 2.32) 1.55 (1.18– 2.03)
Heart failure 2.21 (1.77– 2.76) 1.99 (1.57– 2.51)
Association of diabetes with neurological comorbidities
Stroke 1.46 (1.10– 1.95) 1.39 (1.03– 1.87)
Cognitive 
impairment
1.95 (1.57– 2.44) 1.75 (1.39– 2.21)
Model 1: adjusted for age and sex. 
Model 2: adjusted for age, sex, smoking status, body mass index, and (in 
case hypertension is not the outcome) prevalent hypertension. 
OR indicates odds ratio.
*Data on history of hypertension and history of myocardial infarction were 
available in 2411 participants. Data on history of heart failure and data on 
history of stroke were available in 2409 and 2410 participants, respectively. 
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phenotype and cardiac and neurological comorbidi-
ties in patients who have AF with and without diabetes. 
The study was embedded within a large and well- 
characterized cohort of patients with AF. In our study 
population, we had detailed and extensive information 
on cardiovascular risk factors, AF type, AF symptoms, 
and cardiac and neurological comorbidities. The defi-
nitions of paroxysmal, persistent, and permanent AF 
were based on AF guidelines. Another strength is the 
utilization of a standardized methodology for data col-
lection. Our analyses were adjusted for relevant po-
tential confounders, and multiple sensitivity analyses 
provided consistent findings.
Several potential limitations should also be acknowl-
edged. The diagnosis of diabetes was based on the 
medical history of participants rather than laboratory 
criteria. Therefore, the prevalence of diabetes in our 
population might have been underreported. Also, we 
did not have data available on the duration of diabetes 
or the degree of glycemic control. Nevertheless, we 
had extensive information on insulin and noninsulin- 
based treatments. Furthermore, the cross- sectional 
design does not allow us to draw conclusions on cau-
sality. The possibility of residual confounding cannot 
be excluded in an observational study. Last, the gen-
eralizability of our findings to other populations needs 
to be further investigated.
CONCLUSIONS
In the Swiss- AF cohort population, we showed that pa-
tients with diabetes less often perceive AF symptoms 
Figure 1. Association of diabetes with atrial fibrillation (AF) phenotype and cardiac and neurological comorbidities.
A, Age- and sex- adjusted odds ratios (ORs) and 95% CIs are derived based on logistic regression. The vertical line represents an OR 
of 1. B, Age- and sex- adjusted beta regression coefficient (β) and 95% CIs are derived based on linear regression. The vertical line 
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than those without diabetes. This finding suggests that 
we may need to increase vigilance for AF detection in 
patients with diabetes, further raising the question of 
whether patients with diabetes should be systemati-
cally screened for silent AF. The reduced perception of 
AF symptoms in patients with diabetes might result in a 
delayed AF diagnosis and consequently more adverse 
events, especially cardioembolic stroke. Cardiac au-
tonomic neuropathy is the most plausible mechanism 
through which diabetes can reduce the perception 
of AF symptoms, and further mediation analyses are 
needed to verify this hypothesis. In addition, our study 
shows that patients with diabetes have an increased 
likelihood of comorbidities and decreased quality of 
life, which indicates that patients who have AF with 
diabetes may deserve more attentive care compared 
with those without diabetes.
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Table S1. Association of antidiabetic medication with specific AF symptoms (n, 
2411)† 
Model 1 Model 2 
OR (95% CI) OR (95% CI) 
Palpitations 
No diabetes 1 (Reference) 1 (Reference) 
Non-insulin-requiring diabetes 0.78 (0.59; 1.02) 0.76 (0.57; 1.00) 
Insulin-requiring diabetes 0.41 (0.26; 0.66) 0.40 (0.25; 0.64) 
Dizzeness 
No diabetes 1 (Reference) 1 (Reference) 
Non-insulin requiring diabetes 1.15 (0.81; 1.63) 1.15 (0.80; 1.63) 
Insulin-requiring diabetes 1.08 (0.64; 1.81) 1.08 (0.64; 1.81) 
Chest pain 
No diabetes 1 (Reference) 1 (Reference) 
Non-insulin-requiring diabetes 1.27 (0.84; 1.90) 1.22 (0.81; 1.84) 
Insulin-requiring diabetes 1.50 (0.86; 2.61) 1.46 (0.84; 2.54) 
Exercise intolerance 
No diabetes 1 (Reference) 1 (Reference) 
Non-insulin-requiring diabetes 0.85 (0.62; 1.16) 0.86 (0.62; 1.17) 
Insulin-requiring diabetes 0.57 (0.34; 0.96) 0.57 (0.34; 0.96) 
Dyspnea 
No diabetes 1 (Reference) 1 (Reference) 
Non-insulin-requiring diabetes 1.16 (0.87; 1.55) 1.13 (0.85; 1.51) 
Insulin-requiring diabetes 0.88 (0.56; 1.36) 0.84 (0.54; 1.31) 
Tiredness 
No diabetes 1 (Reference) 1 (Reference) 
Non-insulin-requiring diabetes 0.96 (0.68; 1.37) 0.98 (0.69; 1.40) 
Insulin-requiring diabetes 1.12 (0.69; 1.83) 1.12 (0.68; 1.83) 
Syncope 
No diabetes 1 (Reference) 1 (Reference) 
Non-insulin-requiring diabetes 1.25 (0.65; 2.42) 1.22 (0.63; 2.36) 
Insulin-requiring diabetes 0.50 (0.12; 2.09) 0.49 (0.12; 2.05) 
Other symptoms 
No diabetes 1 (Reference) 1 (Reference) 
Non-insulin-requiring diabetes 0.70 (0.46; 1.05) 0.69 (0.46; 1.04) 
Insulin-requiring diabetes 0.72 (0.39; 1.30) 0.71 (0.39; 1.28) 
Model 1: adjusted for age and sex. 
Model 2: adjusted for age, sex, use of beta-blockers, and use of antiarrhythmic medications. 
† For this analysis, participants were classified into patients without diabetes (reference), patients with non-insulin-requiring diabetes, and 































Table S2. Association of diabetes with the domains of quality of life score† (n, 2411) 
                             
 
Model 1 Model 2 
 OR (95% CI) OR (95% CI) 
Impaired mobility 2.28 (1.82; 2.87) 1.59 (1.25; 2.02) 
Impaired self-care 3.90 (2.57; 5.93) 3.20 (2.06; 4.95) 
Impaired usual activities 2.49 (1.91; 3.25) 2.05 (1.55; 2.70) 
Pain/discomfort 1.44 (1.16; 1.79) 1.14 (0.91; 1.43) 
Anxiety/depression 1.02 (0.78; 1.34) 0.95 (0.72; 1.26) 
Model 1: adjusted for age and sex 
Model 2: adjusted for age, sex, smoking status, body mass index, and prevalent hypertension.  
† The quality of life score was based on European Quality of life-5 Dimensions questionnaire (EQ-5D). EQ-5D was composed of five 
domains, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 




































Table S3. Baseline characteristics of participants with and without data available on left atrial 


















Age, years 73.2 (8.4) 73.2 (8.4) 73.2 (8.4)  72.5 (8.6) 73.5 (8.3) 
Women, n (%) 661 (27.4) 132 (27.7) 529 (27.4) 193 (27.1) 468 (27.6) 
Smoking, n (%)      
Current 175 (7.3)                          31 (6.5) 144 (7.4) 47 (6.6) 128 (7.5) 
Former         1180 (48.9)   233 (48.9) 947 (48.9) 355 (49.9) 825 (48.5) 
Never      1056 (43.8) 212 (44.5) 844 (43.7) 309 (43.5) 747 (43.9) 
Body mass index, kg/m2 27.7 (4.7) 27.6 (4.5) 27.6 (4.8) 27.6 (4.7) 27.6 (4.8) 
Systolic blood pressure, mm Hg 133.8 (18.7) 134.9 (19.1) 133.5 (18.6) 133.9 (18.9) 133.8 (18.6) 
Diastolic blood pressure, mm Hg 77.3 (11.8) 78.1 (11.8) 77.2 (11.8) 78.1 (11.9) 77 (11.8) 
Diabetes mellitus, n (%) 420 (17.4) 74 (15.5) 346 (17.9) 115 (16.2) 305 (18) 
History of hypertension, n (%) 1684 (69.8) 314 (66) 1370 (70.8) 472 (66.4) 1212 (71.3) 
History of myocardial infarction, n (%) 390 (16.2) 78 (16.4) 312 (16.1) 114 (16) 276 (16.2) 
History of heart failure, n (%) 625 (25.9) 113 (23.7) 512 (26.5) 175 (24.6) 450 (26.5) 
History of stroke, n (%) 318 (13.2) 62 (13) 256 (13.2) 90 (12.7) 228 (13.4) 
Quality of life 72.1 (17.4) 72.04 (18.4) 72.23 (17.2) 72.79 (17.6) 71.95 (17.4) 
† Data are presented as mean (standard deviation), unless otherwise specified.  
The quality of life score ranges from 0 to 100, with higher values indicating better quality of life. 







































Table S4. Association of diabetes and antidiabetic medication with 
echocardiographic parameters in AF patients†   
 Model 1 Model 2 
 β (95% CI) β (95% CI) 
Association of diabetes with echocardiographic parameters  
Left atrial size (mm)           1.47 (-0.46; 3.40)  0.27 (-1.70; 2.23) 
Left ventricular ejection fraction (%) -1.63 (-3.90; 0.64) -0.09 (-1.97; 1.79) 
   
Association of antidiabetic medication with echocardiographic parameters‡ 
Left atrial size (mm)          
No diabetes 0 (Reference)  0 (Reference)  
Non-insulin-requiring diabetes 1.24 (-0.97; 3.46)  0.05 (-2.19; 2.29) 
Insulin-requiring diabetes 2.07 (-1.42; 5.55)  0.85 (-2.61; 4.30) 
   
Left ventricular ejection fraction (%)   
No diabetes  0 (Reference)  0 (Reference) 
Non-insulin-requiring diabetes -1.47 (-4.07; 1.14) -1.56 (-4.26; 1.13) 
Insulin-requiring diabetes -2.07 (-6.16; 2.02) -2.31 (-6.51; 1.88) 
Model 1: adjusted for age and sex. 
Model 2: adjusted for age, sex, smoking status, body mass index, and prevalent hypertension.  
† Data on left atrial size and ejection fraction were available in a subsample of 476 and 711 participants, respectively.  The beta 
regression coefficients indicate the predicted differences in mean echocardiographic parameters between categories of diabetes 
status. 
‡ For this analysis, participants were classified into patients without diabetes (reference), patients with non-insulin-requiring diabetes, 
and patients with insulin-requiring diabetes. 




































Table S5. Association of diabetes with AF phenotype, cardiac and neurological 
comorbidities, additionally adjusting for RCI and use of anticoagulation 
medication* 
 Additionally adjusting for 
RCI 
Additionally adjusting for 
use of anticoagulation 
medication 
Association of diabetes with AF phenotype 
Non-paroxysmal AF, OR (95% CI)  1.04 (0.82; 1.30)  1.01 (0.80; 1.26) 
Any AF symptoms, OR (95% CI)  0.75 (0.60; 0.92)  0.73 (0.59; 0.91) 
Quality of life, β (95% CI)  -4.50 (-6.37;-2.64) -4.53 (-6.39;-2.67) 
   
Association of diabetes with cardiac comorbidities 
Hypertension, OR (95% CI) 2.98 (2.15; 4.14) 3.03 (2.18; 4.21) 
Myocardial infarction, OR (95% CI)          1.53 (1.17; 2.01) 1.55 (1.18; 2.03) 
Heart failure, OR (95% CI)  2.02 (1.59; 2.55) 1.99 (1.58; 2.52) 
   
Association of diabetes with neurological comorbidities 
Stroke, OR (95% CI)  1.34 (1.00; 1.82) 1.38 (1.02; 1.86) 
Cognitive impairment, OR (95% CI) 1.74 (1.38; 2.19) 1.76 (1.40; 2.21) 
*Model 2 in the main analyses (reported in Table 2 and Table 3) was additionally adjusted for RCI and use of anticoagulation 
medication, respectively. Data on AF phenotype, history of hypertension and history of myocardial infarction were available in 2411 
participants. Data on history of heart failure and data on history of stroke were available in 2409 and 2410 participants, respectively. 
Data on cognitive impairment were available in a 2398 participants. The quality of life score ranges from 0 to 100, with higher values 
indicating a better quality of life. 
RCI was defined as either a history of pulmonary vein isolation and/or electrical cardioversion and/or use of antiarrhythmic 
medications, which altogether represent the most effective RCI currently available. 










Figure S1. Flow chart for selection of study participants with data available on 








































2415 patients with documented AF and data 
available on history of diabetes and antidiabetic 
medication intake 
 
2411 patients with data on AF phenotype (ie, 
AF type, AF symptoms, quality of life) 
3 without information on AF symptoms 
 
 
1 without information on quality of life 
 
 
2415 patients with data on AF type 
 










Figure S2. Flow chart for selection of study participants with data available on 





































2411 patients with available data on AF phenotype  
 
Data available on cardiac comorbidities 
2411 had data on history of hypertension 
2411 had data on history of myocardial infarction 
2409 had data on history of heart failure  
 
 
1 missing on history of stroke  
 
13 missing on neurocognitive 
function 
2 missing on history 
of heart failure 
 
 
Data available on neurological 
comorbidities 
2410 had data on history of stroke 
2398 had data on cognitive impairment  
 
 
476 had data on left atrial size 
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Figure S3. Association of antidiabetic medication with AF phenotype, cardiac 
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For this analysis, participants were classified into: patients without diabetes, patients with non-insulin-requiring diabetes, and 
patients with insulin-requiring diabetes. a. Age- and sex- adjusted OR and 95% CI are derived based on logistic regression. 
The vertical line represents an odds ratio of 1. b. Age- and sex- adjusted β and 95% confidence intervals are derived based on 
linear regression. The vertical line represents a β of 0. The quality of life score ranges from 0 to 100, with higher values 
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